Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.52 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.48 |
| ▸ | RHEB | Q15382 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.44 |
| ▸ | CFD | P00746 | 1/20 | 0.44 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25925383 | 0.84 | SMN1; SMN2 (0.53) | PTGDR2KMT2ACREBBPALDH1A1LMNA | |
| SCHEMBL17023330 | 0.84 | KMT2A (0.49) | KMT2ACREBBPALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL17023318 | 0.83 | KMT2A (0.48) | PTGDR2KMT2ACREBBPALDH1A1LMNA | |
| SCHEMBL29781763 | 0.83 | KMT2A (0.48) | PTGDR2KMT2ACREBBPALDH1A1LMNA | |
| SCHEMBL613546 | 0.82 | KDM4E (0.67) | PTGDR2MCL1KMT2ARHEBALDH1A1 | |
| SCHEMBL22441037 | 0.81 | PTGDR2 (0.56) | PTGDR2MCL1KMT2ARHEBAKR1B1 | |
| SCHEMBL12480721 | 0.81 | PKM (0.51) | KMT2ACREBBPALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL12480269 | 0.80 | CNR1 (0.47) | PTGDR2KMT2ACREBBPALDH1A1LMNA | |
| SCHEMBL29781911 | 0.79 | KMT2A (0.73) | KMT2ACREBBPALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL12479832 | 0.79 | KMT2A (0.73) | KMT2ACREBBPALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2661433-B1 | INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | NOVARTIS AG (CH) | 2017-08-16 | — | — | EP | disclosed |
| EP-2661433-B1 | INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | NOVARTIS AG (CH) | 2017-08-16 | — | — | EP | disclosed |
| US-9085555-B2 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2015-07-21 | — | — | US | disclosed |
| US-9085555-B2 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2015-07-21 | — | — | US | disclosed |
| US-9085555-B2 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2015-07-21 | — | — | US | disclosed |
| EP-2661433-A1 | INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | Novartis AG (CH) | 2013-11-13 | — | — | EP | disclosed |
| US-20120295884-A1 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2012-11-22 | — | — | US | disclosed |
| US-20120295884-A1 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2012-11-22 | — | — | US | disclosed |
| US-20120295884-A1 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2012-11-22 | — | — | US | disclosed |
| WO-2012093101-A1 | INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | NOVARTIS AG (CH) | 2012-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295884-A1 | Complement pathway modulators and uses thereof | C5, C3AR1, C9 | PTGDR2 1167/4885MCL1 3063/4885KMT2A 4723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.